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Background: Familial long QT syndrome (LQTS) is a primary arrhythmogenic disorder caused by muta-
tions in ion channel genes. The phenotype ranges from asymptomatic individuals to sudden cardiac
arrest and death. LQTS is a rare but signiﬁcant health problem for which global data should exist. This
study sought to provide the ﬁrst clinical and genetic description of Australian families with LQTS.
Methods: We performed a cross-sectional study to evaluate clinical and genetic features of families with
LQTS. We recruited individuals from the Australian Genetic Heart Disease Registry and Genetic Heart
Disease Clinic, in Sydney, Australia, and included those with a diagnosis of LQTS according to the most
recent consensus statement.
Results: Among 108 families with LQTS, 173 individuals were affected. Twenty-ﬁve (32%) probands had a
sudden cardiac death (SCD) event (including appropriate implantable cardioverter deﬁbrillator [ICD]
therapy, or resuscitated cardiac arrest). There were 64 (82%) probands who underwent genetic testing,
and 34 (53%) had a pathogenic or likely pathogenic mutation in. Having a family history of LQTS was
signiﬁcantly associated with identiﬁcation of a pathogenic result (79% versus 14%, po0.0001). There
were 16 (9%) participants who experienced delay to diagnosis of at least 12 months.
Conclusions: This is the ﬁrst clinical and genetic study in a large cohort of Australian families with LQTS.
Findings from this study suggest that the clinical and genetic features in this population are not dis-
similar to those described in North American, European, and Asian cohorts. Global-scale information
about families with LQTS is an important initiative to ensure diagnostic and management approaches are
applicable to different populations and ethnicities.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Familial long QT syndrome (LQTS) is a primary arrhythmogenic
disorder caused by ion channel abnormalities leading to abnormal
ventricular repolarization and a prolonged QT interval on theblished by Elsevier B.V. This is an
ecular Cardiology, Centenary
lia. Tel.: þ61 2 9565 6195.
Semsarian).electrocardiogram (ECG) [1]. Clinical manifestations include pal-
pitations, syncope, or cardiac arrest due to torsade de points and
ventricular ﬁbrillation (VF) [1,2]. Familial LQTS, mostly inherited as
an autosomal dominant trait, rarely presents as a recessive trait in
the form of Jervell and Lange–Nielsen syndrome [3,4].
Clinical diagnosis is based on the identiﬁcation of a prolonged
QT interval on the ECG, presence or absence of a family history,
and absence of QT-prolonging medications [2]. Advances in the
understanding of molecular genetics and pathogenesis of genetic
heart diseases have contributed extensively to elucidating the roleopen access article under the CC BY-NC-ND license
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diseases, the yield of genetic testing has been highest in LQTS, and
is now an integral part of clinical management of families [6].
Particularly, apart from playing a role in diagnosis, genotype also
has potential therapeutic and prognostic implications, with gen-
otype–phenotype correlations shown to explain some of the het-
erogeneity of the disease [6–8].
At least 15 genes are associated with familial LQTS, with 3 of
these genes accounting for 70–75% of cases [5]. Despite advances
in the understanding of the molecular basis of LQTS, challenges
remain in making the clinical diagnosis. Importantly, between 10–
40% of gene carriers have normal QT intervals [9,10]. While
molecular genetics has contributed to improvements in some
aspects of diagnosis, due to the variability of the QT interval and
variable penetrance and expressivity, there is still evidence of
signiﬁcant misdiagnosis and delay in diagnosis [11]. Studies that
describe the clinical and genetic features of LQTS have been mainly
from Europe, North America, and Asia. To our knowledge, there are
no reports of cohorts with LQTS from Australia. With a prevalence
of 1:2000–3000 [12,13], LQTS is a rare but signiﬁcant health pro-
blem, and thus, clinical and genetic data from a range of countries
and ethnicities are important. This study sought to report the
clinical and genetic features of a registry-based cohort of Aus-
tralian families with LQTS.2. Materials and methods
2.1. Patient cohort
All probands and relatives with LQTS attending Royal Prince
Alfred Hospital (RPAH) Genetic Heart Disease Clinic in Sydney,
Australia, or those enrolled in the Australian Genetic Heart Disease
(AGHD) Registry were included [14]. The AGHD Registry aims to
recruit all Australians with a genetic heart disease, and partici-
pants are recruited or self-referred from all states in Australia.
Patients meeting expert consensus recommendations for LQTS
diagnosis were included [2]. In most cases, the proband was
deﬁned as the ﬁrst affected family member who sought medical
advice for LQTS. All studies were conducted in strict accordance
with ethics protocols approved by the Human Research Ethics
Committee at Royal Prince Alfred Hospital, Sydney (Approval
number X11-0077), Australia.
2.2. Clinical diagnosis
Clinical diagnosis was based on the recent HRS/EHRA/APHRS
expert consensus guidelines [2]. Speciﬁcally, a diagnosis was made
in the presence of an LQTS risk scoreZ3.5 in the absence of a
secondary cause of QT prolongation, and/or in the presence of an
unequivocally pathogenic mutation in one of the LQTS genes, or a
QTCZ500 ms in repeated 12-lead ECG without a secondary cause
for QT prolongation.
2.3. Genetic analysis
Genetic test results were recorded if testing had been pre-
viously performed. An amended version of the updated 2015
American College of Medical Genetics (ACMG) standards and
guidelines document was used to determine the pathogenicity of
LQTS variants [15]. Key determinants of pathogenicity included
rarity (o0.05% or absence from the large Exome Aggregation
Consortium dataset, http://exac.broadinstitute.org), agreement
amongst in silico tools (CADD [Combined Annotation-Detection
Depletion], SIFT [Sorting Intolerant From Intolerant, http://sift-
dna.org/], Polyphen-2 [Polymorhism phenotyping Ver2 http://genetics.bwh.harvard.edu/pph2/], MutationTaster [www.muta
tiontaster.org]) of a possibly deleterious role, previous association
of the variant within LQTS patients, segregation data, as well as
available and supportive experimental data. Individuals who did
not meet the clinical diagnosis but harbored variants classiﬁed as
pathogenic or likely pathogenic using this criterion were included
after being considered as meeting the expert consensus recom-
mendations. Topological placement of variants was done using a
combination of Uniprot (http://ca.expasy.org/uniprot/), Human
Protein Reference Database (http://www.hprd.org/Motifs_details/
CC), and a review of the literature [16].
2.4. Collection of clinical and genetic information
Clinical and genetic information were obtained by review of the
medical record and direct correspondence with the treating car-
diologist. The QT interval was measured in lead II or V5 and cor-
rected for heart rate according to Bazett's formula (QTc). Where
there was more than 1 ECG available, the longest QTc was recor-
ded. A sudden cardiac death (SCD) event was deﬁned as SCD,
resuscitated cardiac arrest, or appropriate ICD shock for ven-
tricular tachycardia (VT) or ventricular ﬁbrillation (VF). A family
history of LQTS was considered when at least 1 other relative had a
clinical diagnosis. Delay to diagnosis was deﬁned as the period
between the initial presentation of the symptoms likely attribu-
table to LQTS up to the time of diagnosis in the proband. Delay in
diagnosis was only considered when the time to diagnosis was at
least 12 months.
2.5. Statistical analysis
Data were analyzed using Prism (version 6.0) and SPSS Statis-
tics (version 20.0). Descriptive statistics were used to describe
clinical and genetic features of probands, relatives, and families.
Associations between variables and outcome factors were assessed
using unpaired t-tests for continuous data and chi-square analysis
for categorical data. A p-value of o0.05 was considered statisti-
cally signiﬁcant.3. Results
3.1. Clinical characteristics of LQTS probands and families
A total of 219 individuals were identiﬁed with a possible,
probable, or conﬁrmed diagnosis of LQTS. Thirty-one probands
and 15 relatives were excluded from the analysis as they did not
meet the HRS/EHRA/APHRS expert consensus guidelines for
inclusion. A total of 173 individuals from 108 families with LQTS in
the clinical and genetic characterization (Fig. 1). Ancestry data was
available for 47 probands; the majority (40 ([85%]) of these pro-
bands self-reported Northwest European (Caucasian) ancestry. The
mean follow-up time for probands was 2 years (0–13 years).
A total of 78 probands (from 108 families; the remaining 30
probands were not enrolled in the AGHD Registry) and 95 relatives
meeting diagnostic criteria were identiﬁed; the demographic and
clinical characteristics are summarized in Table 1. The mean age of
probands was 40718 years and 21 (27%) were males. The mean
age at diagnosis was 32718 years, and the mean corrected QT
(QTc) was 515746 ms. There were 39 (50%) probands who had a
documented episode of syncope, and 25 (32%) had experienced an
SCD event, including 3 SCD cases, 22 resuscitated cardiac arrests,
1 appropriate ICD therapy for VT, and 4 appropriate ICD therapies
for VF. The SCD event was the presenting symptom in 21 (27%)
probands. There were 66 (85%) probands on beta-blocker therapy
Fig. 1. Flow chart of genetic testing outcomes in LQTS families. A total of 173 individuals from 108 families were identiﬁed for inclusion in this study. LP, likely pathogenic; P,
pathogenic; VUS, variant of uncertain signiﬁcance; FHx, family history; GT, genetic testing; dx, diagnosis.
Table 1
Demographic and clinical characteristics of the cohort with LQTS.
Variable Probands Relatives p-value
n 78 95 –
Mean age (years) 40718 34722 0.038
Mean age at diagnosis (years) 32718 25722 0.027
Male (n, %) 21 (27) 44 (46) 0.009
North West European Ethnicity (n, %) 40 (85) 45 (47) Not applicable
Delay to dx (n, %) 13 (17) 3 (3) 0.002
Mean QTc (ms) 515746 479741 o0.0001
QTcZ500 ms (n, %) 43 (61) 27 (29) o0.0001
Documented syncope (n, %) 39 (50) 11 (12) o0.0001
ICD in situ (n, %) 40 (51) 15 (16) o0.0001
SCD event (n, %) 25 (32) 2 (2) o0.0001
Appropriate ICD therapy for VF (n, %) 4 (10) 1 (6) 0.113
Appropriate ICD therapy for VT (n, %) 1 (3) 1 (6) 0.889
SCD 3 (4) 0 o0.0001
OHCA 22 (28) 1 (1) o0.0001
Beta Blocker therapy (n, %) 66 (85) 79 (83) 0.838
Family history of LQTS (n, %) 38 (49) 95 (100) Not applicable
Genetic test (n, %) 64 (82) 84 (88) 0.238
Pathogenic or Likely Pathogenic genetic
result (n, %)
34 (53) 83 (99) Not applicable
SCD event, including sudden cardiac death, resuscitated cardiac arrest and appropriate
VT/VF ICD therapy; ICD, implantable cardioverter deﬁbrillator; mean7standard
deviation (SD).
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family history of LQTS.
Of the 108 families (including families where the proband was
not known to the center), 70 (65%) had a family history of LQTS
(i.e. 2 or more individuals with a clinical diagnosis of LQTS). Thirty-
three (31%) families had a history of SCD and 26 (24%) reported a
history of epilepsy, sudden infant death syndrome, unexplained
drowning, miscarriage, frequent “blackouts”, or hearing loss.
3.2. Genetic characteristics of LQTS families
Genetic testing was performed in 88 (81%) families with a
pathogenic or likely pathogenic result identiﬁed in 68 (77%). The
mean number of affected family members per family in a 3 gen-
erational family pedigree was 4 (median, 2; range, 0–28). Of 64
probands tested, 34 (53%) had a pathogenic or likely pathogenic
mutation identiﬁed. Amongst the probands, the median number of
genes screened was 6. There were 4 probands with multiple gene
variants identiﬁed, including 1 with a likely pathogenic and a
pathogenic KCNQ1 mutation in cis, 1 with a pathogenic KCNH2mutation and an additional variant of uncertain signiﬁcance (VUS)
in KCNH2 in trans, 1 proband with a likely pathogenic variant in
KCNQ1 and a VUS in CACNA1C, and 1 proband with a KCNJ2 VUS in
addition to a likely pathogenic KCNH2 variant.
Nine probands had a VUS in a known LQTS gene in which co-
segregation studies had not been completed to clarify causation. In
addition, there were 18 relatives enrolled in the AGHDR (without
the proband) resulting in a total of 62 variants (pathogenic, likely
pathogenic, and VUS) in this cohort of affected individuals (Sup-
plementary Table 1). Of the relatives who underwent cascade
testing, 29 variants were identiﬁed in KCNQ1 (47%), 22 in KCNH2
(35%), 3 in SCN5A (5%), 4 variants in CACNA1C (6%), 2 in KCNE2
(3%), and 2 in KCNJ2 (3%). Characteristics of these variants are
summarized in Table 2. The majority of variants identiﬁed were
missense mutations, (74%) classiﬁed as likely pathogenic (53%). Of
the variants in this cohort, 18 (29%) were novel and not previously
published in the literature. The compendium of LQTS variants from
this cohort by genomic location, nucleotide, protein change, and
region are summarized in the Supplementary Table 1.
3.3. Factors associated with a greater mutation pick-up rate in LQTS
probands
A family history of LQTS was a signiﬁcant predictor of a positive
genetic result, with a causative variant identiﬁed in 27 (79%) of
those with a positive family history of LQTS compared to 3 (14%) of
those with no apparent history or reportedly affected relatives
(po0.0001). Further, the QTc interval was signiﬁcantly longer in
probands with a pathogenic or likely pathogenic variant than in
those where no variant was identiﬁed following genetic testing
(excluding VUS; 523755 ms versus 496723 ms, p¼0.045). Other
clinical characteristics and basic demographics were not asso-
ciated with a positive genetic result (Table 3).
3.4. Genotype–phenotype correlation
There were no signiﬁcant differences when comparing pro-
bands with KCNQ1, KCNH2, or variants in SCN5A, CACNA1C, KCNJ2,
and KCNE2 (excluding VUS). Although the numbers were small,
when comparing probands with 1 pathogenic or likely pathogenic
variant versus those with 2 variants, the QTc was signiﬁcantly
longer in probands with 2 versus 1 variant (578779 versus
513745, p¼0.028), irrespective of the variant classiﬁcation
(Table 4). The location of mutations in the transmembrane or pore
Table 2
Summary of variants identiﬁed in Australian families with LQTS.
KCNQ1 KCNH2 SCN5A CACNA1C KCNE2 KCNJ2 Total
Total (n) 29 22 3 4 2 2 62
Probands 22 9 2 3 2 1 39
Mean age (years) 34718 41717 36745 26712 45711 39 –
Male (n, %) 7 (32) 4 (44) 1 (50) 1 (33) 0 0 –
Syncope (n, %) 9 (41) 6 (67) 1 (50) 3 (100) 0 1 –
Mean QTc (ms) 520753 515741 524779 497717 578788 529 –
Appropriate ICD therapy for VF (n, %) 0 0 0 0 1 (50) NA –
Appropriate ICD therapy for VT (n, %) 0 0 0 0 0 NA –
Beta Blocker (n, %) 17 (77) 6 (67) 1 (50) 1 (33) 2 (100) 1
Pathogenic (n, %) 9 (31) 4 (18) 2 (67) 0 0 0 15 (24)
Likely pathogenic (n, %) 16 (55) 14 (64) 1 (33) 1 (25) 1 (50) 0 33 (53)
Uncertain (n, %) 4 (14) 4 (18) 0 3 (75) 1 (50) 2 (100) 14 (23)
Missense (n, %) 24 (83) 12 (55) 2 (67) 4 (100) 2 (100) 2 (100) 46 (74)
Nonsense (n, %) 3 (10) 5 (23) 0 0 0 0 8 (13)
Frameshift (n, %) 2 (7) 2 (9) 0 0 0 0 4 (6)
Splice site (n, %) 0 2 (9) 0 0 0 0 2 (3)
In-frame INDELS(n, %) 0 1 (5) 1 (33) 0 0 0 2 (3)
Novel (n, %) 4 (14) 10 (45) 0 2 (50) 1 (50) 1 (50) 18 (29)
Data analysis for age, gender, syncope, QTc, and therapies conducted on probands only. Probands with 41 variant excluded from this analysis.
Table 3






n (excluding VUS/ no
testing)
34 21 –
Mean age (years) 37719 43718 0.261
Mean age at diagnosis
(years)
28719 35719 0.193
Male (n, %) 12 (35) 4 (19) 0.205
Mean QTc (ms) 523755 496723 0.045
QTc (ms)Z500 (n,%) 16 (47) 10 (48) 0.433
Documented syncope (n,
%)
17 (50) 8 (38) 0.244
SCD event (n, %) 11 (32) 8 (38) 0.671
ICD in situ (n, %) 15 (44) 13 (62) 0.207
Family history of LQTS
(n, %)
27 (79) 3 (14) o 0.0001
SCD event, including sudden cardiac death, resuscitated cardiac arrest and appro-
priate VT/VF ICD therapy; ICD, implantable cardioverter deﬁbrillator; LP, likely
pathogenic; P, pathogenic; mean7standard deviation (SD). Those with a VUS were
removed from this analysis.
Table 4
Compound heterozygosity in Australian families with LQTS.
Variable 1 pathogenic variant Z2 varianta p-value
n 30 4 –
Mean age (years) 38719 35714 0.801
Mean age at diagnosis (years) 29719 26717 0.788
Male (n, %) 11 (37) 1 (25) 0.646
Mean QTc (ms) 513745 578779 0.0269
QTc (ms)Z500 (n, %) 12 (40) 4 (100) 0.0773
Documented syncope (n, %) 15 (50) 2 (50) 0.842
SCD event (n, %) 10 (33) 1 (25) 0.747
ICD in situ (n, %) 14 (47) 1 (25) 0.428
Family history of LQTS (n, %) 24 (80)` 3 (75) 0.823
SCD event, including sudden cardiac death, resuscitated cardiac arrest and appropriate
VT/VF ICD therapy; ICD, implantable cardioverter deﬁbrillator; mean7standard
deviation (SD).
a Includes those with any rare variant, i.e. VUS, likely pathogenic and patho-
genic.
C. Burns et al. / Journal of Arrhythmia 32 (2016) 456–461 459regions was not associated with poorer prognosis, though the
numbers were small in each subgroup.
3.5. Delay to diagnosis
There were 16 (9%) participants (probands and relatives) who
experienced a delay in diagnosis, including 11 who were initially
misdiagnosed (Supplementary Table 2). Speciﬁcally, 8 were mis-
diagnosed with epilepsy, 1 with catecholaminergic polymorphic
ventricular tachycardia (CPVT), 1 with nocturnal seizures, and
1 with anxiety. Of the 16 who experienced a delay in diagnosis, 4
(25%) had a likely pathogenic or pathogenic variant in KCNH2,with
1 participant found to have a VUS in KCNH2, 4 (25%) carrying likely
pathogenic or pathogenic variants in KCNQ1, as well as 1 additional
participant with a VUS in KCNQ1. One participant had a VUS in
KCNJ2 and 1 carried a likely pathogenic variant in CACNA1C. Two
participants from the misdiagnosed group had indeterminate
genetic testing and 2 had not had genetic testing at the time of
analysis. The mean delay to diagnosis was 8 years (1–20 years). In
this group, the earliest investigation year recorded was 1973 and
the most recent was 2010. Importantly, the mean delay decreasedover time, from a mean of 12 years when the ﬁrst presentation was
before the year 2000, to 5 years from the year 2000 onwards.3.6. More severe phenotype in probands compared to relatives
The characteristics of relatives are summarized alongside pro-
bands in Table 1. There were signiﬁcant differences in the clinical
and demographic variables between relatives and probands.
Relatives were younger (p¼0.038), diagnosed at a younger age
(p¼0.027), and were more likely to be of male sex (p¼0.009).
Relatives had shorter QT intervals (po0.0001), less documented
syncope (po0.0001), and fewer SCD events (po0.0001). Fifteen
(16%) relatives had an ICD in situ, including 1 who had experienced
an appropriate ICD shock for VF and 1 who had experienced an ICD
shock for VT. There was no difference in terms of beta-blocker use
between relatives and probands (83% versus 85% p¼0.838).
The mean QTc for probands with a pathogenic or likely
pathogenic result was 523755 ms (458–660) and for probands
without a genetic result was 496723 ms (460–540) (p¼0.045).
Relatives with known and genotyped LQTS exhibited wide-ranging
QT intervals 479741 ms (400–620) (po0.0001) (Supplementary
Fig. 1). Sixteen (20%) genotyped relatives for whom QTc was
available had a QTc interval within the normal range of r440 ms.
C. Burns et al. / Journal of Arrhythmia 32 (2016) 456–4614604. Discussion
4.1. Main ﬁndings
To our knowledge, this is the ﬁrst clinical and genetic report of
Australian families with LQTS. The key clinical and genetic char-
acteristics of Australian families are not dissimilar to those pre-
viously described for European, North American, and Asian
cohorts with LQTS. Global information about families with LQTS is
an important initiative to ensure diagnostic, and management
approaches are applicable to different populations and ethnicities.
Further, delay in diagnosis and gene carriers with normal QT
intervals emphasize the diagnostic challenges that LQTS can pre-
sent in clinical practice, and highlight the importance of genetic
testing in the management of these families.
4.2. Genetic testing outcomes in LQTS
Genetic testing of probands in our LQTS cohort had a yield of
53%, less than that reported in the literature of 65–75% [7]. In the
current study, the genetic testing yield was higher (79%) in those
with a positive family history of LQTS, emphasizing the impor-
tance of obtaining a comprehensive 3-generation pedigree where
possible, consistent with recent ﬁndings of family history being a
predictor of a positive genetic result in other genetic heart diseases
such as hypertrophic cardiomyopathy [17,18]. In services where
funding restrictions exist, identiﬁcation of individuals with LQTS
with a high pre-test probability of a variant being identiﬁed is
valuable and represents the most cost-effective strategy [19,20].
The current study also contributes to the compendium of LQTS-
associated genetic variants published in the literature. Eighteen
(29%) novel variants were identiﬁed in the current cohort, which
was primarily of Caucasian origin, highlighting that many families
still harbor unique “private” mutations. Given the increasing
complexities associated with classifying genetic variants so as to
provide families with meaningful information and data that con-
tributes and may aid in this challenging process is valuable.
4.3. Clinical challenges of LQTS diagnosis
Our study highlights and reinforces the complexity of clinical
diagnosis of LQTS. Delay in diagnosis is a documented issue that
has been observed in several cohorts with LQTS [11,21], as well as
in other inherited arrhythmogenic syndromes [22]. In the current
study, 9% of participants experienced a diagnostic delay of at least
12 months. Given that the ﬁrst investigation dates ranged from the
1970s up until 2010, the ﬁnding highlights the diagnostic chal-
lenge LQTS can present. This seemed particularly true if probands
presented with recurrent syncope or ‘seizure-like activity’ and
whose primary investigations suggested neurological differential
diagnoses rather than cardiac. In a New Zealand study of LQTS
patients, delay in diagnosis was frequent in up to 31 (39%) of
patients with LQTS [23]. The tendency toward recurrent syncope
or “seizure-like activity” can set patients up for a diagnostic
odyssey with LQTS not recognized early as a cause for symptoms.
Adding further complexity to this issue is a recent study in which
the authors suggest that 15% of patients with LQTS presenting
with blackouts or seizure-like activity had electroencephalography
(EEG) identiﬁed epileptiform activity [24]. It is suggested that EEG
activity and epilepsy are more frequent in patients with a KCNH2
(LQT2) mutation. EEG reports were not available in the current
study, but taken together with other reports in the literature,
provide preliminary support for a neuro-cardiac link with KCNH2
encoded potassium channels that are expressed both in the brain
and the heart. This further reinforces the need for continuededucation and awareness among primary care physicians, as well
as emergency physicians and general cardiologists.
4.4. Australian LQTS in the international context
The main characteristics of LQTS in the international literature,
including demographics, SCD events, genotype frequencies, and
normal QTc intervals in genotyped patients, were also demonstrated
in this Australian cohort. The current study aligned with larger
international studies [6,10,25] and, therefore, allows available evi-
dence to be extrapolated to an Australian context. The AGHD Registry
represents the largest genetic heart disease population in Australia
[14]. Indeed, the current study is a reminder of the need for coop-
erative, collaborative efforts in genetic heart disease research, where
a lack of randomized controlled trials upon which to base disease
management guidelines exist. Collaborative initiatives and truly
international cohorts with LQTS are therefore critical to address
fundamental questions relating to diagnosis, risk stratiﬁcation, clin-
ical management, and genotype-guided management.
4.5. Study limitations
Although this is the ﬁrst study to provide insight into the
clinical and genetic features of Australian families with LQTS, this
cohort is not truly population-based. Recruiting from the AGHD
Registry is likely to have introduced sampling bias whereby those
individuals enrolled represent a more severe spectrum of disease.
Statistical analysis was limited by the relatively small sample size
and highlights the value of a large collaborative initiative.5. Conclusions
LQTS is a rare but signiﬁcant health problem, the most tragic
outcome of which is SCD. To our knowledge, this is the ﬁrst cohort
study to describe the clinical and genetic characteristics of Australian
families with LQTS. The study highlights the complex challenges in
the clinical diagnosis of LQTS. Coupled with continued difﬁculties in
clinical diagnosis, the key role of genetic testing is further empha-
sized. By reporting and contributing to the compendium of LQTS
associated variants, this data may provide valuable information to
LQTS groups globally, with the ultimate goal to improve the diagnosis
and management of families with LQTS.Conﬂict of interest
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